2017
DOI: 10.1007/s11010-017-3106-x
|View full text |Cite
|
Sign up to set email alerts
|

Oxytocin participates on the effects of vasoactive intestinal peptide on food intake and plasma parameters

Abstract: Vasoactive intestinal peptide (VIP) is a neurotransmitter with anorectic effect that acts in the hypothalamus to regulate food intake. Oxytocin is a neuropeptide produced in the hypothalamus that controls energy homeostasis and has an inhibitory role on food intake. Thus, the present study aims at verifying the role of oxytocin as a mediator of VIP on energy homeostasis. For this purpose, intracerebroventricular microinjection of oxytocin receptor antagonist (vasotocin, OVT) or vehicle (NaCl 0.9%) was carried … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2018
2018
2022
2022

Publication Types

Select...
6

Relationship

0
6

Authors

Journals

citations
Cited by 6 publications
(2 citation statements)
references
References 43 publications
0
2
0
Order By: Relevance
“…Vasoactive intestinal peptide (VIP) is widely distributed in neural tissue and the gastrointestinal tract, inhibits gastrointestinal motility, delays gastric emptying, and slows small intestine motility [29]. Calcitonin gene-related peptide (CGRP) is widely distributed in the gastrointestinal tract neural plexus.…”
Section: Discussionmentioning
confidence: 99%
“…Vasoactive intestinal peptide (VIP) is widely distributed in neural tissue and the gastrointestinal tract, inhibits gastrointestinal motility, delays gastric emptying, and slows small intestine motility [29]. Calcitonin gene-related peptide (CGRP) is widely distributed in the gastrointestinal tract neural plexus.…”
Section: Discussionmentioning
confidence: 99%
“…Vasoactive intestinal peptide (VIP) is a 28-residue neuropeptide, which is abundant in the respiratory system (Martins et al, 2018). VIP is involved in various acute and chronic inflammatory disorders, such as septic shock, rheumatic arthritis, and asthma (Gonzalez-Rey et al, 2007;Guan et al, 2009;Sun et al, 2011).…”
Section: Introductionmentioning
confidence: 99%